Investment Thesis
Twist Bioscience demonstrates solid 20.3% revenue growth in a capital-intensive biotech sector but faces significant operational headwinds with -36.7% operating margins and -$60.2M annual free cash flow burn. The company's fortress balance sheet (zero meaningful debt, $122.7M cash, 2.70x current ratio) provides 2+ year runway, but path to profitability remains unclear with continuing $78.8M operating losses on $214.4M revenue.
Strengths
- Strong revenue growth momentum at 20.3% YoY in competitive biotech sector
- Pristine balance sheet with zero debt, $122.7M cash, and 2.70x current ratio enabling financial flexibility
- Improving loss metrics with 63.9% YoY EPS improvement indicates operational progress toward breakeven
Risks
- Severe operating losses consuming $78.8M (-36.7% margin) on $214.4M revenue with no path to profitability visible
- Negative free cash flow of $60.2M annually creates finite runway of ~2 years at current burn rate
- R&D-intensive biological products sector requires sustained capital investment to maintain competitive position
Key Metrics to Watch
- Operating margin trajectory - critical inflection toward positive territory needed
- Free cash flow sustainability - when does operating cash flow turn positive?
- Gross margin (unreported) - essential for assessing underlying unit economics and pricing power
- Cash runway depletion rate - with $122.7M cash and -$60.2M FCF, timeline to cash shortage
Financial Metrics
Revenue
214.4M
Net Income
-74.5M
EPS (Diluted)
$-1.21
Free Cash Flow
-60.2M
Total Assets
676.2M
Cash
122.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-36.7%
Net Margin
-34.8%
ROE
-16.4%
ROA
-11.0%
FCF Margin
-28.1%
Balance Sheet & Liquidity
Current Ratio
2.70x
Quick Ratio
2.42x
Debt/Equity
0.00x
Debt/Assets
32.7%
Interest Coverage
N/A
Long-term Debt
833.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T21:09:22.275075 |
Data as of: 2026-03-31 |
Powered by Claude AI